Events

Cambridge Science Festival / Anne Phelan

AI Hype vs. Reality

Data science and AI have the potential to transform the discovery and development of medicines. However, there is a lot of hype surrounding AI. The session will cover: What has been achieved to date? What is realistic to expect from data science and AI in the next 5 to 10 years? How can data science experts manage expectations? How can pharma and tech better collaborate to realise the potential of data science and AI in healthcare?

The interdisciplinary panel will be chaired by Gareth Mitchell, presenter from the BBC's Digital Planet.

Panellists include:

  • Dr Jim Weatherall (Vice President of Data Science & AI, R&D, AstraZeneca),
  • Professor Mihaela van der Schaar (Director, Cambridge Centre for AI in Medicine),
  • Anne Phelan (CSO, BenevolentAI)
  • Dr Junaid Bajwa (Chief Medical Scientist, Microsoft Research).

Register here →


Anne Phelan

Chief Scientific Officer

Anne is Chief Scientific Officer, Head of Preclinical Development and Site Head for the Benevolent Cambridge Laboratories. Anne is responsible for driving the early AI augmented discovery portfolio through Lead Optimisation to delivery of pre-clinical candidate drug molecules. Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stage development

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021